๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

19 recruiting trials

for EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy NCT07375316Phase 24 sites๐Ÿ“ Guangzhou๐Ÿ“ Meizhou๐Ÿ“ Shantou Guangdong Association of Clinical Trials ยท Tests: Osimertinib + Sacituzumab Tirumotecan, Osimertinib A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Guangzhou Henan Genuine Biotech Co., Ltd. ยท Tests: Dositinib mesylate tablets A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer NCT06631989Phase 1, Phase 212 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Guangzhou Wayshine Biopharm, Inc. ยท Tests: WSD0922-FU Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer NCT06755684Phase 21 site๐Ÿ“ Shanghai Peng Zhang ยท Tests: Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site๐Ÿ“ Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. ยท Tests: Almonertinib, Placebo Almonertinib A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871Phase 153 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Aurora Iambic Therapeutics, Inc ยท Tests: IAM1363 A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer NCT07538804Phase 1, Phase 25 sites๐Ÿ“ Fairfax๐Ÿ“ Guangzhou๐Ÿ“ Harbin Avistone Biotechnology Co., Ltd. ยท Tests: ANS02 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site๐Ÿ“ Guangzhou Guangdong Association of Clinical Trials ยท Tests: Ivonescimab Injection The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558Phase 1, Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: LMV-12(HE003) A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT05442060Phase 27 sites๐Ÿ“ Taipei๐Ÿ“ Taipei๐Ÿ“ Taoyuan OBI Pharma, Inc ยท Tests: 30 ฮผg OBI-833/100 ฮผg OBI-821, Erlotinib (150 mg daily) A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC NCT06962865Phase 234 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Binzhou RemeGen Co., Ltd. ยท Tests: RC108, Furmonertinib Mesilate Tablets Monotherapy APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors NCT03175224Phase 235 sites๐Ÿ“ Los Angeles๐Ÿ“ Tampa๐Ÿ“ Boston Apollomics Inc. ยท Tests: APL-101 Oral Capsules Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT06350097Phase 3167 sites๐Ÿ“ Fountain Valley๐Ÿ“ Los Alamitos๐Ÿ“ Los Angeles AstraZeneca ยท Tests: Osimertinib, Datopotamab Deruxtecan Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) NCT05598528n/a1 site๐Ÿ“ Changsha Second Xiangya Hospital of Central South University ยท Tests: Genomic profiles detection, circulating tumor DNA detection Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA NCT05334277Phase 226 sites๐Ÿ“ Changchun๐Ÿ“ Chengdu๐Ÿ“ Dongguan Sun Yat-sen University ยท Tests: Furmonertinib, Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: ORIENT-31 regimen, SBRT Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer NCT07315113Phase 16 sites๐Ÿ“ Calverton๐Ÿ“ Boston๐Ÿ“ Eugene Nuvectis Pharma, Inc. ยท Tests: NXP900, Osimertinib
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy